Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results From a Proof-of-Concept, Phase Ib Study
Nom du journal : Clin Cancer Res
Année : 2021
Volume : 28
Page de départ : 1087
Page de fin : 1097